Nanomedicines
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

Nanomedicines

  • 238 views
Uploaded on

Nanomedicines. ...

Nanomedicines.
A new nanotechnology platform for nanomedicines from;
www.nanomeda.com

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
238
On Slideshare
238
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
1
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. A unique platform for Nanomedicines Lowest or No upfront price New technology Fastest results Patent protection Branded guarantee Low solubility and bioavailability is a common but a road blocker for many Novel drugs. Typically, companies will have a hit and trial Approach to solve your problem with huge upfront charges. Introducing our newest Hybrid-Nanoengineering™ technology to fix your problem. You will not only have product but a patent protection and a branding for premium price of your product. Are you still looking for the long term investment winner for the next decade? • Only solution to win the race • Join us for that goal • Multiple location to conduct your project ABC llc. Hybrid-Nanoengineering™ Just one statement! We will provide you the best product With patent protection
  • 2. A reliable solution for your success to resolve solubility problem Nanotechnology A solution for solubility Services with patent protection One platform for all Nanoparticles for; Join us To Win Yes or No in three weeks No charge for this work! . Increase bioavailability with efficacy and branding Scalable technology ABC llc. USA
  • 3. Dual Action Nanomedicines Partnering ABC’s Hybrid-Nanoengineering™ drug delivery platform generates more commercial opportunities than we can pursue independently. Strategic partnering is therefore a critical component of our ability to advance our novel therapeutics programs into clinical development and onto the market. Our objective is to selectively partner at strategic stages of the development process while retaining select therapeutic programs to develop independently. We want to strategically integrate our patented technology platform into the best possible companies to insure we achieve the most rapid development of therapeutics which utilize our base technology. This strategy will enable the Company to maximize the number of lead compounds it can rapidly put into development as it continues to harvest output and develop its platform to a higher degree of productivity. Meda pursues the following types of collaborations: Licensing and/or co-development arrangements for our clinical pipeline products and pre-clinical drugs in development. We can collaborate to develop therapeutics from our existing programs of both proteins/peptides and small molecules. Partners may choose to advance these programs independently or in conjunction with us. We can take the newly developed molecules or existing patent expired drugs and put them in our platform to develop next generation of same drug to extent the further life the expired patented drug. One broken part can mean total equipment failure. An imaging technology partner that quickly delivers the parts you need is a lifesaver, sometimes literally. But fast access isn’t enough—replacement parts also have to be quality assured and cost effective. Make us your next partner for nanomedicine and to resolve your; BIOAVAILABILITY PROBLEM Let us resolve together